Dyne Therapeutics Appoints Daniel Wilson as Vice President, Head of Intellectual Property

Mr. Wilson is an experienced intellectual property attorney with deep expertise in drug development

WALTHAM, Mass.--(BUSINESS WIRE)--Dyne Therapeutics, a biotechnology company pioneering life-transforming therapies for patients with serious muscle diseases, today announced the appointment of Daniel Wilson as vice president, head of intellectual property. Mr. Wilson comes to Dyne from Celgene, where he served as senior corporate counsel. He is an accomplished intellectual property attorney with extensive experience leading and executing IP strategy in the biotechnology industry.

Dyne has built a strong IP position to support its FORCE™ platform, which uses highly targeted antibodies to deliver disease-modifying therapeutics directly to skeletal, cardiac and smooth muscle tissue. In his new role, Mr. Wilson will focus on bolstering and expanding Dyne’s IP position across multiple programs.

“Dyne has developed a truly novel and very exciting approach to treating progressive muscle diseases,” said Mr. Wilson. “The team’s recent data presentation underscores the power of the proprietary FORCE platform to deliver durable, functional benefits even at low doses – and to deliver modern oligonucleotide therapeutics for muscle diseases. I’m thrilled to come on board to support and advance Dyne’s intellectual property strategy at this important moment in the company’s development.”

“Dan’s impressive background in intellectual property law and deep experience in drug development will be a valuable asset to Dyne as we continue to enhance our robust IP position and build the leading muscle disease company,” said Joshua Brumm, president and chief executive officer of Dyne. “We look forward to the significant contributions Dan will bring as we advance the development of transformative, highly targeted therapies for myotonic dystrophy, Duchenne muscular dystrophy and other disorders.”

At Celgene, Mr. Wilson led the intellectual property group for Celgene’s Massachusetts office while working on a variety of global business deals, collaborations and product development teams. During his time at Celgene, Mr. Wilson served as patent counsel for the project teams that launched two new medicines. Prior to working at Celgene, Mr. Wilson was intellectual property counsel at Sunovion Pharmaceuticals. He began his legal career working at the law firms of Goodwin Procter and Testa, Hurwitz & Thibeault, where he worked with a variety of life science companies. Mr. Wilson received his B.A. in biology from Swarthmore College, his M.S. in pharmacology from University of Pennsylvania and his J.D. from Boston University School of Law.

About Dyne Therapeutics

Dyne Therapeutics is pioneering life-transforming therapies for patients with serious muscle diseases. The company’s FORCE™ platform delivers oligonucleotides and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision to restore muscle health. Dyne is advancing treatments for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Dyne was founded by Atlas Venture and is headquartered in Waltham, Mass. For more information, please visit www.dyne-tx.com, and follow us on Twitter, LinkedIn and Facebook.